Rockwell Medical Achieves Profitability on an Adjusted EBITDA Basis in the Fourth Quarter 2023 and Record Net Sales, Gross Profit and Gross Margin for the Full-Year 2023
Net sales for the three months ended December 31, 2023 were $22.1 million.
- Net sales for the three months ended December 31, 2023 were $22.1 million.
- Net sales for the twelve months ended December 31, 2023 were $83.6 million, representing a 15% increase over the same period in 2022.
- Gross margin for the twelve months ended December 31, 2023 was 10%, representing an increase from 6% gross margin for the same period in 2022.
- During the fourth quarter of 2023, Rockwell Medical lowered its outstanding debt from $9.5 million to $8.0 million.